Medication info

Mefoglitin Duo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Youngpoong Pharmaceutical Co., Ltd.
Appearance
Bilateral convex orange-colored oval film-coated tablet
Packaging
60 tablets/PTP[(10 tablets/PTP×6)]
Approval status
Expired

MFDS item code 201907771 · Approved 2019.11.06

This product's status changed to Expired on 2024.11.06. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this drug twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience with antidiabetic drug therapy who have difficulty achieving adequate blood glucose control with monotherapy, the initial dose of this drug is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate blood glucose control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at the doses of linagliptin and metformin they were previously taking. 4. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Use with caution in the following patients). 5. Patients who cannot achieve adequate blood glucose control with combination therapy of insulin and metformin: The initial dose of this drug should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Use with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Youngpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in adults with type 2 diabetes. It is administered as an adjunct to diet and exercise to improve blood sugar levels. It may be used in patients who have not previously received diabetes medication or who find it difficult to control blood sugar with monotherapy. It can also be used as a replacement or in combination when sufficient effect is not achieved with monotherapy of metformin or the combination of linagliptin and metformin. It is used in combination with sulfonylureas, insulin, empagliflozin, etc., to further enhance blood sugar control. This medication is used to effectively improve blood sugar control when combined with various treatment methods.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. Administer this drug twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience with antidiabetic drug therapy who have difficulty achieving adequate blood glucose control with monotherapy, the initial dose of this drug is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who cannot achieve adequate blood glucose control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at the doses of linagliptin and metformin they were previously taking. 4. Patients who cannot achieve adequate blood glucose control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Use with caution in the following patients). 5. Patients who cannot achieve adequate blood glucose control with combination therapy of insulin and metformin: The initial dose of this drug should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions, 2. Use with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this drug because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 1. Do not administer to the following patients).

Precautions

This medication can cause a rare but serious side effect known as lactic acidosis, thus it should not be administered, particularly to patients with poor kidney function or liver dysfunction. Patients who have allergies to the active ingredients of this medication or those with type 1 diabetes, severe kidney disease, acute infections, heart failure, liver impairment, acute alcohol intoxication, etc., should not use this medication. Due to the risk of hypoglycemia, when taken in conjunction with insulin or sulfonylureas, blood sugar levels should be closely monitored, and dosage adjustments may be needed as necessary. If symptoms of lactic acidosis such as muscle cramps, abdominal pain, or severe fatigue occur, immediate consultation with a physician is required, and the use of this medication should be temporarily discontinued in situations where kidney function could rapidly deteriorate. Elderly patients with impaired kidney function or unstable renal function should receive regular kidney function tests. Patients with weak heart function should monitor both cardiac and renal function periodically while taking this medication. If iodinated contrast media is used during radiological examinations, it is advised to discontinue this medication for a certain period before and after the examination, and to also discontinue it for a certain period before and after surgery. Rare side effects such as acute pancreatitis or blistering skin diseases may occur; immediate consultation with a physician is required in case of persistent severe abdominal pain or blisters on the skin. While taking this medication, vitamin B12 levels may decrease, so if there are symptoms of anemia or neurological abnormalities, vitamin B12 testing should be conducted. There may be interactions when used with other medications, particularly those that can affect kidney function or glucose-lowering agents, so caution is necessary. It is advisable for pregnant women or those who may become pregnant, as well as nursing mothers, to avoid using this medication, and it is not recommended for pediatric and adolescent patients. Elderly patients are at higher risk of decreased kidney function and should undergo regular testing; it is safest to avoid the maximum dosage and start from the minimum dosage. In case of overdose, gastrointestinal symptoms and lactic acidosis may present, and immediate medical treatment is required, which may include hemodialysis.

Side effects

  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • lactic acidosis
  • reduced and deficient vitamin B12
  • hypoglycemia
  • taste disturbance
  • cough
  • reduced appetite
Show 139 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • diarrhea
  • hypoglycemia
  • stomatitis
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • reduced appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hyperglycemia
  • dyspnea
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • epistaxis
  • itching
  • insomnia
  • depression
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • indigestion
  • epigastric pain
  • hemorrhoidal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • dizziness
  • drowsiness
  • weakness
  • pain
  • male pattern baldness
  • diabetic foot
  • excessive sweating
  • hair loss
  • dermatitis
  • anxiety
  • mood disorders
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • eye discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • urge incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be kept in a tightly sealed container. The recommended storage temperature is between 1°C and 30°C at room temperature. This helps maintain the efficacy of the medication for a long time.

Appearance and packaging

Appearance

Bilateral convex orange-colored oval film-coated tablet

Package unit

60 tablets/PTP[(10 tablets/PTP×6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.